Trial · NCT05513560
RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine
NCT05513560, Phase 2, Phase 3, Completed, University Health Network, Toronto
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine. Trials, record NCT05513560. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05513560
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine
- NCT number
- NCT05513560
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 460 participants, actual
- Lead sponsor
- University Health Network, Toronto
- Conditions
- Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19
- Interventions
- Ibudilast, Pentoxifylline, Placebo
- First posted
- 2022-08-24
- Last updated
- 2026-02-23
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | SF-36 physical component score (PCS) | from baseline to two months | mean change in the SF-36 (v.1) physical component score (PCS) |
| Secondary | Symptoms scale | Baseline/Randomization weekly to 2 months, then once monthly to 6 months. | Three point Likert scale assessing how bothersome symptoms are on a weekly basis for two months then monthly until end of study, as reported by the participant: to provide a granular, detailed picture of the symptom trajectory. |
| Secondary | Symptom Checklist | Baseline/Randomization weekly to 2 months, then once monthly to 6 months. | Symptom Checklist (adapted from the De Paul Symptom Questionnaire (DSQ2), the World Health Organization Global COVID-19 Clinical Platform's Post COVID-19 CRF and the Symptom Burden Questionnaire for Long COVID): to track symptom trajectory. |
| Secondary | Six Minute Walking Test (6MWT) with oximetry | Baseline/Randomization and 2 months | Subjects walk as far as they can in six minutes while receiving maximum encouragement. It is simple to execute, inexpensive, standardized and gives a tangible measure of functional exercise capacity. It has been validated in many different populations. The 6MWT will be conducted according to American Thoracic Society standards. |
| Secondary | TestMyBrain cognitive testing | Baseline/Randomization to 1, 2 months 3 and 6 months | TestMyBrain was developed as a tool to collect large, population-based samples for understanding the relationship between cognition, emotion, social functioning, and health. This test battery will take about 20 minutes to complete and will assess: verbal, episodic and working memory, attention, processing speed, basic psychomotor response speed, and cognitive control. |
| Secondary | Post COVID19 functional status scale | Baseline/Randomization to 1, 2 months 3 and 6 months | The post-COVID-19 functional status (PCFS) scale focuses on relevant aspects of daily life during follow-up after the infection. The scale is intended to help users become aware of current functional limitations in COVID-19 patients, whether or not as a result of the specific infection, and to objectively determine this degree of disability. The scale is ordinal, has 6 steps ranging from 0 (no symptoms) to 5 (death), and covers the entire range of functional outcomes by focusing on limitations in usual duties/activities either at home or at work/study, as well as changes in lifestyle. The PCFS demonstrates good construct validity. |
| Secondary | Reintegration to Normal Living Index (RNLI) | Baseline/Randomization to 1, 2 months 3 and 6 months | This short self-administered assessment tool will determine the degree to which participants reintegrate into normal social activities such as recreation, mobility in the community and interaction in family and other relationships. This tool has been validated in community living adults with mobility limitations. |
| Secondary | Fatigue Scale | Baseline/Randomization to 1, 2 months 3 and 6 months | The Fatigue Scale was adapted from the De Paul Symptom Questionnaire (DSQ2)'s 38 questions assessing medical history of Myalgic Encephalitis/Chronic Fatigue Syndrome (ME/CFS), comorbidities, medications, impact on quality of life and daily activities, etc. |
| Secondary | Brief Fatigue inventory | Baseline/Randomization to 1, 2 months 3 and 6 months | The self-administered Brief Fatigue Inventory is composed of 9 items evaluated on a 10-point scale, assessing severity of fatigue and impact of fatigue on daily life. It takes approximately 2-3 minutes to complete. |
| Secondary | Post-Exertional Malaise | Baseline/Randomization to 1, 2 months 3 and 6 months | The self-administered DPEMQ is comprised of three sections assessing post-exertional malaise (PEM): (i) onset and triggers of PEM (9 questions), (ii) consequences and symptoms (14 questions), (iii) duration, recovery and pacing (7 questions). |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05513560
GET https://conductscience.org/api/trials/v1/NCT05513560/registered